Datum Källa Rubrik Typ Alternativ
2024-04-19 Abliva Abliva publishes rights issue outcome Pressreleaser Ladda ner | Visa Stäng
2024-04-19 Abliva Abliva offentliggör utfall i företrädesemission Pressreleaser Ladda ner | Visa Stäng
2024-04-08 Abliva BioStock: Abliva vill bli en nyckelspelare inom mitokondriell medicin Pressreleaser Visa Stäng
2024-04-08 Abliva BioStock: Abliva's mission to become mitochondrial medicine powerhouse Pressreleaser Visa Stäng
2024-03-27 Abliva Abliva offentliggör prospekt med anledning av företrädesemission som till 100 procent omfattas av tecknings- och garantiåtaganden och upptagande till handel av nyemitterade aktier Pressreleaser Ladda ner | Visa Stäng
2024-03-27 Abliva Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares Pressreleaser Ladda ner | Visa Stäng
2024-03-26 Abliva Beslut vid extra bolagsstämma i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-03-26 Abliva Resolutions at the Extraordinary General Meeting in Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-29 Abliva BioStock: Ablivas vd kommenterar den föreslagna kapitalanskaffningen Pressreleaser Visa Stäng
2024-02-29 Abliva BioStock: Abliva's CEO comments on the proposed capital raise Pressreleaser Visa Stäng
2024-02-27 Penser Future by Carnegie Penser Future by Carnegie: Abliva - Interimdata i sommar Pressreleaser Visa Stäng
2024-02-23 Abliva Abliva AB Bokslutskommuniké januari – december 2023 Rapporter Ladda ner | Visa Stäng
2024-02-23 Abliva Abliva AB Year-End Report January – December 2023 Rapporter Ladda ner | Visa Stäng
Rapporter | 23 Feb 2024 | Abliva

Abliva AB Year-End Report January – December 2023

40 Patients Enrolled in Wave 1 of the FALCON Study | Fast Track Designation for KL1333 | Orphan Drug Designation for NV354 in both US and Europe

2023 Summary

Important events during 2023

KL1333

  • The first patient in Abliva’s global, potentially registrational, clinical Phase 2 study – the FALCON study was dosed in June.
  • Fast Track designation was received in September from the U.S. Food and Drug Administration (FDA), facilitating KL1333’s clinical development and path forward to market.
  • The goal of enrolling 40 patients for Wave 1 of the FALCON study was met in December. The interim analysis remains on track for summer of 2024.

NV354

  • The U.S. Patent and Trademark Office granted a composition of matter patent in February.
  • Orphan Drug Designation (ODD) was granted in April in the U.S. for the treatment of mitochondrial disease.
  • Orphan designation was granted by the European Commission in December for the treatment of Leigh syndrome.

Other

  • Abliva appointed Dag Nesse as Vice President of Clinical Operations in February.
  • World Mitochondrial Disease Week, Septermber 18 – 24, was recognized by Abliva by the release of videos highlighting the ongoing activities at the company. The videos can be found at Abliva’s website www.abliva.com .
  • A licensing and collaboration agreement for Abliva’s NeuroSTAT®, for the treatment of moderate to severe traumatic brain injury (TBI), was signed by Abliva and Owl Therapeutics of San Antonio, Texas (US) in November. See page 17 for more information.

Important events after the reporting period

  • The Board of Directors of Abliva AB has on 22 February resolved on a capital raise totalling app. SEK 88 million through a fully guaranteed rights issue of app. SEK 46 million, and a directed issue of convertible bonds of app. SEK 42 million. The convertible loan amount shall be paid and immediately converted into shares in the Company after the announcement of the interim data from the KL 1333 Phase 2 study provided the results from the study is positive, i.e. non futile. The Transaction is conditional upon approval by an Extraordinary General Meeting intended to be held on March 26, 2024. For further information, see page 10.
  • Abliva convened an Extraordinary General Meeting to be held at 3 p.m. on Tuesday 26 March 2024 at Medicon Village, Scheeletorget 1, in Lund, Sweden, with admission for registration from 2.30 p.m.

Financial information

October-December 2023*

  • Net revenues: SEK 137,000 (0)
  • Other operating income: SEK 0 (1,504,000)
  • Loss before tax: SEK 25,258,000 (17,576,000)
  • Loss per share before dilution: SEK 0.02 (0.04)
  • Diluted loss per share: SEK 0.02 (0.04)

January-December 2023*

  • Net revenues: SEK 137,000 (31,000)
  • Other operating income: SEK 1,345,000 (1,716,000)
  • Loss before tax: SEK 95,518,000 (85,264,000)
  • Loss per share before dilution: SEK 0.09 (0.12)
  • Diluted loss per share: SEK 0.09 (0.12)

* APM Alternative performance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva’s website www.abliva.com .

2024-02-22 Abliva Notice of Extraordinary General Meeting of Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva Kallelse till extra bolagsstämma i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva The Board of Directors of Abliva resolves on a fully guaranteed rights issue of SEK 46 million and a directed issue of convertible bonds of SEK 42 million to prepare for the final stage of the FALCON study Pressreleaser Ladda ner | Visa Stäng
2024-02-22 Abliva Styrelsen för Abliva beslutar om en fullt garanterad företrädesemission om 46 MSEK och en riktad emission av konvertibler om 42 MSEK för att förbereda slutfasen av FALCON-studien med KL1333 Pressreleaser Ladda ner | Visa Stäng
2023-12-21 Abliva BioStock: Abliva når mål för patientinkludering Pressreleaser Visa Stäng
2023-12-21 Abliva BioStock: Abliva reaches enrollment goal Pressreleaser Visa Stäng
2023-12-20 Abliva Abliva når mål för patientinkludering i Steg 1 av FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-12-20 Abliva Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study Pressreleaser Ladda ner | Visa Stäng
2023-12-15 Abliva BioStock: Abliva's CEO: "Orphan drug designation is great validation" Pressreleaser Visa Stäng
2023-12-15 Abliva BioStock: Ablivas vd: "Orphan drug designation is great validation" Pressreleaser Visa Stäng
2023-12-15 Penser Future by Carnegie Penser Future by Carnegie: Abliva - Huvudkonkurrent misslyckas Pressreleaser Visa Stäng
2023-12-14 Penser Future by Carnegie Penser Future by Carnegie: Abliva - 4 minutes by Penser Pressreleaser Visa Stäng
2023-12-14 Abliva Abliva erhåller särläkemedelsklassificering från EU-kommissionen för sin läkemedelskandidat NV354 Pressreleaser Ladda ner | Visa Stäng
2023-12-14 Abliva Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354 Pressreleaser Ladda ner | Visa Stäng
2023-11-20 Penser Future Penser Future: Luft under vingarna - Abliva Pressreleaser Visa Stäng
2023-11-17 Abliva Abliva AB Interim Report January – September 2023 Rapporter Ladda ner | Visa Stäng
2023-11-17 Abliva Abliva AB Delårsrapport januari – september 2023 Rapporter Ladda ner | Visa Stäng
2023-11-16 Abliva BioStock: Abliva signs global license deal for NeuroSTAT Pressreleaser Visa Stäng
2023-11-16 Abliva BioStock: Abliva tecknar globalt licensavtal för NeuroSTAT Pressreleaser Visa Stäng
2023-11-15 Penser Future Penser Future: Licensierar ut NeuroSTAT - Abliva Pressreleaser Visa Stäng
2023-11-14 Abliva Abliva och Owl Therapeutics ingår licens- och samarbetsavtal för NeuroSTAT® vid traumatisk hjärnskada Pressreleaser Ladda ner | Visa Stäng
2023-11-14 Abliva Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury Pressreleaser Ladda ner | Visa Stäng
2023-10-18 Abliva Abliva presenterar på BioStock Life Science Summit den 25 oktober Pressreleaser Visa Stäng
2023-10-18 Abliva BioStock: Ablivas VP of Clinical Operations om uppnått screening-mål Pressreleaser Visa Stäng
2023-10-18 Abliva BioStock: Abliva's VP of Clinical Operations on the screening achievement Pressreleaser Visa Stäng
2023-10-11 Abliva Abliva Achieves Important Milestone in the Ongoing FALCON Study Pressreleaser Ladda ner | Visa Stäng
2023-10-11 Abliva Abliva når viktig milstolpe i den pågående FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Abliva BioStock:Abliva increases awareness of mitochondrial diseases Pressreleaser Visa Stäng
2023-09-19 Abliva BioStock:Abliva ökar medvetenheten om mitkondriella sjukdomar Pressreleaser Visa Stäng
2023-09-18 Abliva Abliva to Participate in World Mitochondrial Disease Week 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-18 Abliva Abliva uppmärksammar World Mitochondrial Disease Week 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-08 Abliva BioStock: Abliva receives FDA Fast Track designation Pressreleaser Visa Stäng
2023-09-08 Abliva BioStock: Abliva erhåller FDA Fast Track-status Pressreleaser Visa Stäng
2023-09-04 Abliva Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation Pressreleaser Ladda ner | Visa Stäng
2023-09-04 Abliva Ablivas huvudkandidat KL1333 får Fast Track-status från FDA Pressreleaser Ladda ner | Visa Stäng
2023-08-21 Penser Future Penser Future: Patientrekrytering i fokus - Abliva Pressreleaser Visa Stäng
2023-08-18 Abliva Abliva AB Delårsrapport januari-juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-18 Abliva Abliva AB Interim Report January – June 2023 Rapporter Ladda ner | Visa Stäng
2023-06-30 Abliva BioStock: First patient dosed in Abliva's Falcon study Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: Första patienten doserad i Ablivas Falcon-studie Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: Första patienten doserad i Ablivas Falcon-studie Pressreleaser Visa Stäng
2023-06-30 Abliva BioStock: First patient dosed in Abliva's Falcon study Pressreleaser Visa Stäng
2023-06-29 Abliva Abliva presents at UMDF Mitochondrial Medicine 2023 Pressreleaser Ladda ner | Visa Stäng
2023-06-29 Abliva Abliva presenterar på UMDF Mitochondrial Medicine 2023 Pressreleaser Ladda ner | Visa Stäng
2023-06-28 Abliva Abliva announces first patient dosed in the FALCON study Pressreleaser Ladda ner | Visa Stäng
2023-06-28 Abliva Abliva meddelar att första patienten doserats i FALCON-studien Pressreleaser Ladda ner | Visa Stäng
2023-06-14 Abliva BioStock: Abliva's presence is felt at Euromit Pressreleaser Visa Stäng
2023-06-14 Abliva BioStock: Ablivas CMO om presentation på Euromit Pressreleaser Visa Stäng
2023-06-12 Abliva Abliva presenterar vetenskapliga data vid internationell konferens inom mitokondriell medicin Pressreleaser Ladda ner | Visa Stäng
2023-06-12 Abliva Abliva presents scientific data at international conference on mitochondrial medicine Pressreleaser Ladda ner | Visa Stäng
2023-05-24 Penser Future Penser Future: Interview with Abliva - Erik Penser Bank - May 24th 2023 Pressreleaser Visa Stäng
2023-05-24 Penser Future Penser Future: Tidsplan för FALCON-studien intakt - Abliva Pressreleaser Visa Stäng
2023-05-23 Abliva Abliva AB Interim Report January – March 2023 Rapporter Ladda ner | Visa Stäng
2023-05-23 Abliva Abliva AB Delårsrapport januari-mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-05 Abliva Beslut vid årsstämma den 5 maj 2023 i Abliva AB (publ) Pressreleaser Ladda ner | Visa Stäng
2023-05-05 Abliva Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Abliva Ändring av valberedningens förslag till Ablivas årsstämma 2023 Pressreleaser Ladda ner | Visa Stäng
2023-05-04 Abliva Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

23 May 2024 | Årsstämma 2023
23 May 2024 | Kvartalsrapport 2024-Q1
24 May 2024 | Årligutdelning
22 Aug 2024 | Kvartalsrapport 2024-Q2
21 Nov 2024 | Kvartalsrapport 2024-Q3
21 Feb 2025 | Bokslutskommuniké 2024